1	Association Between Preoperative Myocardial Perfusion Imaging and Cardiac Events
2	after Elective Noncardiac Surgery
3	
4	
5	Seong-Bong Wee, MD, ¹ Cheol Hyun Lee, MD, ² Tae Joon Jun, PhD, ³ Jung-Min Ahn, MD, ¹
6	Jeong Hwan Yook, MD, ⁴ Jae-Sik Nam, MD, ⁵ In-Cheol Choi, MD, ⁵ Dae Hyuk Moon, MD, ⁶
7	Sangwon Han, MD, ⁶ Hoyun Kim, MD, ¹ Yeonwoo Choi, MD, ¹ Jinho Lee, MD, ¹ Sangyong
8	Cho, MD, ¹ Tae Oh Kim, MD, ¹ Do-Yoon Kang, MD, ¹ Pil Hyung Lee, MD, ¹ Duk-Woo Park,
9	MD, ¹ Soo-Jin Kang, MD, ¹ Seung-Whan Lee, MD, ¹ Young-Hak Kim, MD, ¹ Cheol Whan Lee,
10	MD, ¹ Seong-Wook Park, MD, ¹ David J Cohen, MD, ⁷ and Seung-Jung Park, MD. ¹
11	
12	¹ Division of Cardiology, Heart Institute, Asan Medical Center, University of Ulsan, Seoul,
13	Korea; ² Division of Cardiology, Department of Internal Medicine, Keimyung University
14	Dongsan Hospital, Daegu, Korea; ³ Big Data Research Center, Asan Institute for Life
15	Sciences, Asan Medical Center, Seoul, Korea; ⁴ Department of Surgery, Asan Medical Center,
16	University of Ulsan College of Medicine, Seoul, Korea; ⁵ Department of Anesthesiology and
17	Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;
18	⁶ Department of Nuclear Medicine, Asan Medical Center, University of Ulsan, College of
19	Medicine, Seoul, Korea; ⁷ Department of Cardiology, Saint Francis Hospital and
20	Cardiovascular Research Foundation, NY, NY 10019, USA.
21	
22	The first two authors (SB Wee and CH Lee) equally contributed to this paper.
23	

- 24 Abstract Word Count: 290
- 25 Main Text Word Count: 2942

- 27 Address for correspondence:
- 28 Jung-Min Ahn, MD
- 29 Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine,
- 30 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea
- 31 Telephone: +82-2-3010-5904
- 32 Fax: +82-2-487-5918
- 33 E-mail: drjmahn@gmail.com

34

Abstract

Background There remains a lack of robust evidence regarding the prognostic value of
 myocardial perfusion imaging (MPI) before noncardiac surgery in large and diverse patient
 populations.

38 **Methods** This retrospective observational cohort study from single, tertiary, high surgical 39 volume center in South Korea included 82,441 patients aged >40 years who underwent MPI 40 using pharmacologic stress single photon emission computed tomography within 6 months 41 before elective noncardiac surgery from January 2000 to December 2021. Results of MPI 42 were classified as abnormal (any fixed or reversible perfusion defect) vs normal MPI before 43 noncardiac surgery. The primary outcome was a composite of cardiac death or myocardial infarction within 30 days. 44 45 **Results** Among the 82441 patients (mean±standard deviation age, 65.7±9.6 years; 47417 46 [57.5%] men), 184 (0.2%) experienced cardiac death or myocardial infarction within 30 days 47 after noncardiac surgery. MPI were abnormal in 5603 patients (6.8%). Compared with a 48 normal MPI, an abnormal MPI had a higher risk of the primary outcome (crude incidence, 49 1.2% vs 0.1%; adjusted odds ratio, 4.64; 95% confidence interval, 3.29-6.50; P < .001). The 50 presence of an abnormal MPI improved discrimination for the primary outcome (area under 51 the receiver operating characteristic curve with MPI vs without MPI (0.77 vs 0.73; P<0.001)) 52 and significantly increased net reclassification improvement (0.26; 95% confidence interval, 53 0.11-0.40; P < .001). Among patients with an abnormal MPI, 378 (6.7%) underwent pre-54 operative coronary revascularization; however, this was not associated with a lower risk of

55 the primary outcome (P=.56).

56 **Conclusion** An abnormal myocardial perfusion imaging appeared to be an important risk

- 57 factor for adverse postoperative events and provided additional prognostic value for patients
- ⁵⁸ undergoing noncardiac surgery. Nevertheless, preoperative MPI was limited by its low
- 59 positive predictive value for postoperative cardiac events, leading to potentially unnecessary
- 60 coronary revascularization procedures with unproven prognostic value.

61 Clinical Perspectives

62 What is new?

63	•	This study included the largest population to date and included a broad spectrum of
64		patient and surgical procedures compared with previous studies limited by relatively
65		small sample sizes and low event rates.
66	•	Preoperative abnormal MPI results were significantly associated with the
67		postoperative risk of cardiac death and myocardial infarction in patients undergoing
68		noncardiac surgery, and provided incremental prognostic value beyond clincial
69		assement only.
70		
71	What a	re the clinical implications?
72	•	Our study suggested that MPI appears warranted, particularly for patients with a
73		considerable surgical risk.
74	•	However, its low positive predictive value, and unproven prognostic value of
75		coronary revascularization triggered by MPI should be taken into account in the
76		clincial practice.

77 Introduction

Every year, ≥200 million adults undergo major noncardiac surgery and its number is still
increasing.^{1,2} Despite the overall safety of contemporary noncardiac surgery, approximately
10% of these patients experience post-operative complications.³ Cardiovascular
complications remain the leading cause of death within 30 days of noncardiac surgery.⁴

82 Therefore, identification of patients at high cardiovascular risk during preoperative

83 consultation is important.

Previous studies have revealed that abnormal features upon myocardial perfusion 84 imaging (MPI) indicate an increased risk of perioperative cardiac complications.⁵ Current 85 86 practice guidelines recommend stress MPI prior to non-cardiac surgery for patients with both 87 elevated risk of major adverse cardiac events and poor functional capacity especially if testing impacts decision-making or perioperative care.⁴ The uncertain value of pre-operative 88 MPI derives from its low diagnostic yield, the unclear clinical benefit of preoperative 89 90 revascularization triggered by its results, and the potential for unnecessary delays of surgical treatment.^{6,7} Notably, previous studies on preoperative MPI were limited by their small 91 samples and numbers of events.⁸ Most studies were performed on the highest-risk patients 92 93 (eg, those undergoing vascular surgery) decades ago, and the application of those results in 94 today's practice is unclear, given advances in both surgery and perioperative care. In addition, 95 the predictive discrimination associated with MPI has not been adequately compared with those derived from preoperative risk calculators alone.⁹ Nevertheless, preoperative MPI and 96 subsequent revascularization are frequently performed in real-world practice to evaluate 97 cardiac risk in an effort to prevent perioperative cardiac complications.¹⁰⁻¹² 98



To address these gaps in contemporary evidence, we performed a retrospective, real-

100	world study:	(1)) determine the	prognostic	value of r	oreo	perative MPI to	predict	cardiac	events
		< - /	,							

- 101 after elective noncardiac surgery; and (2) examine the clinical benefit of selective coronary
- 102 angiography and revascularization in response to abnormal MPI.
- 103
- 104 Methods
- 105 Study Design and Study Population

106 This was a single-center, retrospective observational cohort study, and was conducted using

107 data from the Asan Biomedical Research Environment (ABLE), which is a de-identified

108 clinical database of Asan Medical Center, a 2700-bed tertiary hospital in Seoul, South Korea.

109 This data warehouse contains all medical records of our center, including electronic medical

110 records, international classification of disease codes, laboratory findings, imaging data, and

111 medications in an anonymized form.¹³

112 The study population was drawn from all patients who underwent MPI in the 6 months 113 prior to elective noncardiac surgery under general anesthesia between January 2000 and 114 December 2021. Patients were excluded if they met any of the following criteria: younger 115 than 40 years of age; undergoing an emergency operation; experiencing acute myocardial 116 infarction in the month before surgery; undergoing cardiac surgery; undergoing nonsurgical 117 procedures (eg, bronchoscopy, endoscopy, cystoscopy, and percutaneous vascular or 118 nonvascular procedures); undergoing minor surgery with minimal sedation or local 119 anesthesia, such as skin, dental, and ophthalmologic procedures. Only the index procedure of 120 patients undergoing multiple eligible procedures during the study period was used for 121 analyses. Additional inclusion and exclusion criteria are summarized in the Supplement 122 Appendix.

This study conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the institutional review board of Asan Medical Center. The need for written informed consent was waived. No industry was involved in the design, conduct, or analysis of the study.

127

128 Data Extraction and Collection

129 Patient demographics, comorbidities, prescriptions, laboratory data, types of surgeries, and

130 outcomes were obtained via the ABLE system by researchers who were blinded to the

131 process of data analysis. Comorbidities diagnosed prior to the date of noncardiac surgery

132 were electronically obtained using the Korean Standard Classification of Diseases and Causes

133 of Death (KCD-7), which was developed based on the International Classification of

134 Diseases, 10th revision (Supplement).¹⁴ In addition, the revised cardiac risk index (RCRI),

135 which consists of six identifiable predictive factors (high-risk surgery [intraperitoneal,

136 intrathoracic, and suprainguinal vascular surgery], ischemic heart disease, congestive heart

137 failure, cerebrovascular disease, diabetes mellitus controlled with insulin therapy, and renal

138 dysfunction [serum creatinine concentration >2.0 mg/dL]), was calculated. All 1436 types of

139 surgeries performed in the study population were reviewed and classified as low- or high-risk

140 surgeries based on prior expert consensus (Supplement Appendix).^{15,16}

141

142 Myocardial Perfusion Imaging

143 Single photon emission computed tomography with thallium-201 (Tl-201) was used to

144 acquire myocardial perfusion images via a standardized protocol, as previously described.¹⁷

145 Pharmacologic stress was induced with intravenous infusion of either adenosine (0.14

146	mg/kg/min for 6 min) or dipyridamole (0.56 mg/kg/min for 4 min). At peak stress, a 44.4-
147	148.0-MBq dose of 201-Tl was intravenously injected, depending on the patient's body
148	weight and the type of gamma camera used. Post-stress and redistribution MPIs were
149	acquired with one of the following camera systems equipped with a conventional Anger
150	camera or cadmium-zinc-telluride detectors: Triad 88 or XLT (Trionix Research Laboratory,
151	Twinsberg, OH, USA); ADAC or Precedence 16 (Philips Healthcare, Best, The Netherlands);
152	E.Cam, Symbia T2, or Evo Excel (Siemens Healthineers, Erlangen, Germany); Infinia,
153	Ventri, Discovery NM830, or NM530c (GE Healthcare, Waukesha, WI, USA). Specific
154	acquisition parameters depended on the type of camera.
155	MPI was primarily analyzed qualitatively by experienced nuclear medicine physicians
156	(D.H.M. and S.W.H) as a normal or abnormal. ¹⁷ Subsequently, abnormal results were further
157	classified into fixed perfusion defects only or any reversible perfusion defect. In addition,
158	semi-quantitative analysis, performed using a 20-segment model and a five-point scale, was
159	used to calculate the summed stress score, summed rest score, and summed difference score
160	(SDS). The SDS was converted into a percentage of total myocardium by dividing it by the
161	maximum potential score (4 \times 20) to assess the ischemic burden (% ischemic
162	myocardium). ^{18,19}
163	
164	Study Outcomes and Follow-up

165 The primary outcome in this study was the composite of cardiac death or myocardial

166 infarction within 30 days after elective noncardiac surgery. Cardiac death was defined as

- 167 sudden death or death secondary to a proximate cardiac cause, including cardiac arrest,
- 168 myocardial infarction, low-output failure, or fatal arrhythmia. Myocardial infarction was

169	defined as an elevation of cardiac enzymes with associated signs and symptoms of ischemia
170	felt to be caused by coronary atherothrombosis. The secondary outcomes were cardiac death,
171	all-cause death, and myocardial infarction within 30 days after elective noncardiac surgery.
172	The mortality data was confirmed by cross-referencing with the Korean National Health
173	Insurance Service, which is a single-payer program of a universal health coverage system and
174	mandatory health care in Korea. ²⁰ In addition, all medical records and other source
175	documents were carefully reviewed, by two physicians (S.B.W. and C.H.L), blinded to MPI
176	results, to validate the diagnosis of cardiac death and myocardial infarction. Myocardial
177	injury after noncardiac surgery (MINS) was defined as a postoperative cardiac troponin
178	concentration above the 99 th percentile of the upper reference limit of the assay without
179	evidence of nonischemic etiology among patients who underwent a routine troponin test after
180	noncardiac surgery. ²¹ Definitions of the study outcomes are provided in the Supplement
181	Appendix.

182

183 Statistical Analysis

184 Baseline characteristics of the patients are reported as frequencies and percentages for 185 categorical variables and means with standard deviations for continuous variables. Survival 186 was assessed using the Kaplan-Meier method and compared using the log-rank test. We compared the primary and secondary outcomes according to the MPI results by using logistic 187 regression models, and the final multivariable models included age, sex, the RCRI, and MPI 188 results. These covariates were selected a priori based on previous evidence.²² Odds ratios 189 190 (ORs) and corresponding 95% confidence intervals (CIs) were reported. We assessed the risk prediction and stratification performance of MPI by calculating the area under the time-191

192	dependent receiver operating characteristic (ROC) curve and the continuous net
193	reclassification improvement (NRI). Because of the potential for type I error due to multiple
194	comparisons, for which we did not adjust for the P values, results of analyses for secondary
195	outcomes should be interpreted as exploratory. All reported P values are two-sided. A P value
196	<.05 was considered statistically significant. Analyses were performed using R software,
197	version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria).
198	
199	Results
200	Characteristics of the Population
201	From January 2000 to December 2021, 82,441 patients who underwent MPI for preoperative
202	cardiac risk assessment before elective noncardiac surgery were included in this study, of
203	whom 5603 (6.8%) had an abnormal MPI (Figure 1). The patients' mean age was 65.7±9.6
204	years, 57.5% were men, 50.2% underwent high-risk surgery, and 12.2% had an RCRI score
205	\geq 2 (Table 1). Compared with patients with normal MPI, patients with abnormal MPI were
206	more likely to have comorbidities. The frequency of abnormal MPI increased as the RCRI
207	score increased, ranging from 2.4% among patients with an RCRI 0 to 50.3% in patients with
208	RCRI \geq 4 (Figure 2).
209	

210 Primary and Secondary Outcomes

At 30 days, 82388 (99.9%) of patients were completed clinical follow-up. The primary

212 outcomes (the composite of cardiac death or myocardial infarction) occurred in 184 patients

- 213 (97 cardiac deaths and 100 myocardial infarctions) within 30 days of elective noncardiac
- surgery. The causes of death are summarized in eTable 1. Figure 3 demonstrates that the

215	cumulative incidences of the primary and secondary outcomes were all significantly higher
216	among patients with abnormal MPI results than among those with normal results. As
217	summarized in Table 2, the risk of the primary outcome was significantly higher in patients
218	with abnormal MPI than in those with normal results (crude incidence, 1.2% vs 0.1%;
219	adjusted OR, 4.64; 95% CI, 3.29 to 6.50; P<.001). Similarly, cardiac death (0.5% vs 0.1%;
220	adjusted OR, 3.11; 95% CI, 1.86 to 5.07; P<.001), death from any cause (1.0% vs 0.5%;
221	adjusted OR, 1.41; 95% CI, 1.03 to 1.89; P=.026), and myocardial infarction (0.9% vs 0.1%;
222	adjusted OR, 8.19; 95% CI, 5.21 to 12.87; P<.001) were more frequent in patients with
223	abnormal MPI. Among 23934 patients who underwent routine troponin testing after
224	noncardiac surgery, the risk of MINS was also significantly higher in patients with abnormal
225	MPI (16.5% vs 13.2%; adjusted OR, 1.37; 95% CI, 1.23 to 1.52; P<.001), as indicated in
226	Table 2 and eFigure 1.
227	When abnormal MPI findings were classified as fixed only or reversible, the primary
228	outcome more frequently occurred among patients with a fixed defect only (adjusted OR,
229	3.42; 95% CI, 1.94 to 5.69; $P \le .001$) and those with a reversible perfusion defect (adjusted
230	
200	OR, 5.26; 95% CI, 3.62 to 7.57; P <.001) than it did among patients with normal MPI, as
231	OR, 5.26; 95% CI, 3.62 to 7.57; P <.001) than it did among patients with normal MPI, as demonstrated in eFigure 2A and eTable 2. In addition, the risk of the primary outcome
231 232	OR, 5.26; 95% CI, 3.62 to 7.57; P <.001) than it did among patients with normal MPI, as demonstrated in eFigure 2A and eTable 2. In addition, the risk of the primary outcome increased according to the extent of ischemia. Compared with <5% ischemic burden
231 232 233	OR, 5.26; 95% CI, 3.62 to 7.57; P <.001) than it did among patients with normal MPI, as demonstrated in eFigure 2A and eTable 2. In addition, the risk of the primary outcome increased according to the extent of ischemia. Compared with <5% ischemic burden (reference category), the adjusted OR for 5-10% ischemic burden was 1.47 (95% CI, 0.94 to
231 232 233 234	OR, 5.26; 95% CI, 3.62 to 7.57; P <.001) than it did among patients with normal MPI, as demonstrated in eFigure 2A and eTable 2. In addition, the risk of the primary outcome increased according to the extent of ischemia. Compared with <5% ischemic burden (reference category), the adjusted OR for 5-10% ischemic burden was 1.47 (95% CI, 0.94 to 2.23; P =0.080), while >10% ischemic burden was associated with an adjusted OR of 3.52
231 232 233 234 235	OR, 5.26; 95% CI, 3.62 to 7.57; P <.001) than it did among patients with normal MPI, as demonstrated in eFigure 2A and eTable 2. In addition, the risk of the primary outcome increased according to the extent of ischemia. Compared with <5% ischemic burden (reference category), the adjusted OR for 5-10% ischemic burden was 1.47 (95% CI, 0.94 to 2.23; P =0.080), while >10% ischemic burden was associated with an adjusted OR of 3.52 (95% CI, 2.07 to 5.70; P <.001) (eFigure 2B and eTable 2).

237 Subgroup Analysis

238	Figure 4 demonstrates the incidence of the primary and secondary outcomes according to the
239	RCRI score. The risk of cardiac death or MI increased with increasing RCRI score. The
240	prognostic impact of an abnormal MPI on the risk of cardiac death or MI was more
241	prominent in patients with low RCRI risk category (P for interaction <.001). Nevertheless,
242	even among the highest risk group (patients with RCRI ≥ 2 and abnormal MPI), the absolute
243	risk of cardiac death or MI was only 1.5% at 30 days. Additional subgroup analyses
244	according to the clinical subgroup and types of surgery, which consistently showed the higher
245	risk of primary outcome in patients with abnormal MPI, were summarized in eFigure 3 and
246	eFigure 4.
247	
248	Prognostic Performance of MPI before Noncardiac Surgery
248 249	Prognostic Performance of MPI before Noncardiac Surgery The presence of an abnormal MPI improved discrimination for the primary outcome (AUC
248 249 250	Prognostic Performance of MPI before Noncardiac SurgeryThe presence of an abnormal MPI improved discrimination for the primary outcome (AUCwith MPI vs without MPI [0.77 vs 0.73; P<0.001]) and significantly increased NRI (0.26,
248 249 250 251	Prognostic Performance of MPI before Noncardiac SurgeryThe presence of an abnormal MPI improved discrimination for the primary outcome (AUCwith MPI vs without MPI [0.77 vs 0.73; P<0.001]) and significantly increased NRI (0.26,
248 249 250 251 252	Prognostic Performance of MPI before Noncardiac SurgeryThe presence of an abnormal MPI improved discrimination for the primary outcome (AUCwith MPI vs without MPI [0.77 vs 0.73; P<0.001]) and significantly increased NRI (0.26,
248 249 250 251 252 253	Prognostic Performance of MPI before Noncardiac SurgeryThe presence of an abnormal MPI improved discrimination for the primary outcome (AUCwith MPI vs without MPI [0.77 vs 0.73; P<0.001]) and significantly increased NRI (0.26,
248 249 250 251 252 253 253	Prognostic Performance of MPI before Noncardiac SurgeryThe presence of an abnormal MPI improved discrimination for the primary outcome (AUCwith MPI vs without MPI [0.77 vs 0.73; P<0.001]) and significantly increased NRI (0.26,
248 249 250 251 252 253 254 255	Prognostic Performance of MPI before Noncardiac Surgery The presence of an abnormal MPI improved discrimination for the primary outcome (AUC with MPI vs without MPI [0.77 vs 0.73; <i>P</i> <0.001]) and significantly increased NRI (0.26, 95% CI, 0.11-0.40; <i>P</i> <0.001). These significant improvements were driven mainly by improved discrimination for myocardial infarction. The model including adjustment for abnormal MPI results yielded good discrimination performance for myocardial infarction (AUC=0.83).
248 249 250 251 252 253 254 255 256	Prognostic Performance of MPI before Noncardiac SurgeryThe presence of an abnormal MPI improved discrimination for the primary outcome (AUCwith MPI vs without MPI [0.77 vs 0.73; P<0.001]) and significantly increased NRI (0.26,

angiography, and subsequently, 378 underwent coronary revascularization (260 percutaneous

- coronary interventions and 118 coronary artery bypass graft surgeries) before elective
- 260 noncardiac surgery. Among patients with abnormal MPI, patient who underwent coronary

- angiography or revascularization were not significantly associated with the lower risk of the 261
- 262 primary outcome within 30 days of noncardiac surgery (Figure 5).
- 263

264 Discussion

- 265 This large, observational study identified a significant association between an abnormal
- 266 preoperative MPI and the composite of cardiac death or myocardial infarction within 30 days
- 267 of noncardiac surgery—an association that increased progressively according to the extent of
- 268 myocardial ischemia. When compared with standard clinical risk factors, the use of
- 269 preoperative MPI testing led to a significant improvement in discrimination as well as
- 270 substantial reclassification of risk as assessed by the net reclassification index. Nonetheless,
- 271 given the low overall incidence of post-operative cardiac events in the study population, the
- 272 positive predictive value of an abnormal MPI study to predict postoperative cardiac event
- 273 was low (1.2%), leading to potentially unnecessary coronary angiography and
- 274 revascularization procedures with unproven prognostic value.
- 275 Previous studies have examined a role for MPI in stratification of perioperative cardiac risk, but the results have been mixed.^{5,23-25} A meta-analysis of nine studies including 1,179
- 276
- 277 patients undergoing noncardiac vascular surgery revealed that reversible defects in >20% of

myocardial segments were significantly associated with perioperative complications.⁵ 278

- 279 Another study suggested that incorporation of MPI may improve perioperative risk
- 280 assessment of patients with obstructive disease upon coronary computed tomography
- angiography.²³ However, other studies have shown that routine use of MPI before abdominal 281
- aortic surgery did not predict the risk of cardiac complications^{26,27} and did not improve 282
- patient risk classification beyond essential assessment using age, RCRI, and surgical 283

priority.²⁸ However, These previous studies were limited by relatively small sample sizes and low event rates, inclusion of mainly patients undergoing relatively high-risk vascular surgery, and the use of outdated perfusion imaging techniques and perioperative management.^{15,29} In contrast, our study included the largest population to date and included a broad spectrum of patients and surgical procedures across the full risk spectrum, thus demonstrating the consistent prognostic utility of MPI for predicting perioperative cardiac risk in contemporary practice.

291 Current clinical guidelines do not support the routine use of MPI in preoperative risk 292 assessment and rather recommend a subjective assessment of functional capacity as an initial step for preoperative cardiac risk assessment.^{9,30} Typically, preoperative MPI is recommended 293 294 only for patients with both elevated risk of major adverse cardiac events and poor exercise capacity. However, a recent prospective cohort study has revealed that subjective assessments 295 296 of functional capacity are neither an accurate predictors of exercise capacity based on formal cardiopulmonary testing nor associated with the risk of post-operative cardiac events.²² 297 298 Moreover, recent studies suggested that the prevalence of poor functional capacity is 299 relatively low in clinical practice, and the most patients who experience postoperative cardiac complications had satisfactory preoperative functional capacities.³¹⁻³³ Therefore, our 300 301 study suggested that more liberal use of MPI, ungated by functional capacity, is seemingly 302 warranted, particularly in patients with a considerable surgical risk. 303 Prior to our study, there was little information on the value of preoperative noninvasive stress testing in low-risk patients.^{24,29} Our study, which included 32498 patients with 304

- 305 RCRI 0, demonstrated that even among low-risk patients, an abnormal MPI study was
- 306 significantly associated with an increased risk of post-operative cardiac events. In addition,

the prognostic impact of abnormal MPI was more prominent in patients with low cardiac risk. 307 308 Nonetheless, given that the incidence of an abnormal MPI in low-risk patients (RCRI 0) was 309 only 2.4% and the incidence of cardiac death or MI among these individuals was only 1.0%, 310 the value of routine preoperative MPI testing in low-risk population should be interpreted in 311 the context of the appropriate use of medical resources and cost-effectiveness in real practice. 312 The original justification for preoperative MPI was to identify patients with significant 313 myocardial ischemia who would potentially benefit from coronary revascularization prior to 314 noncardiac surgery. However, this hypothesis was refuted by the randomized trials which demonstrated no clinical benefit of coronary revascularization before noncardiac surgerv³⁴⁻³⁷ 315 316 - results that are reinforced by our observational data. Therefore, our study suggested that 317 preoperative MPI should not be the sole indication for preoperative invasive coronary 318 angiography and subsequent coronary revascularization in stable elective surgical candidates, 319 which is supported by recent randomized trial in patients with stable ischemic heart disease.³⁸ 320 Nonetheless, previous observational study has suggested an association between performing preoperative MPI and reduced rate of perioperative mortality after noncardiac surgery.²⁹ 321 322 These findings suggest that clinical benefits associated with preoperative MPI may be 323 explained by mechanisms other than coronary revascularization such as careful 324 anesthesiologic care, meticulous perioperative medical surveillance and management, 325 changes in surgical technique, mostly towards a less invasive approach, or even deferring 326 surgery in some very high risk patients. Further prospective study is necessary to evaluate 327 whether performing preoperative MPI and subsequent changes in surgical and medical 328 management of patient would improve postoperative cardiac outcomes. 329 Our study has several limitations. First, it was a retrospective observational study.

330	Therefore, the possibility of residual confounding in the associations cannot be eliminated
331	despite the statistical adjustments we made for several key clinical characteristics. Second,
332	our data sources did not capture information on exercise tolerance. Third, biomarkers for
333	perioperative myocardial necrosis were not obtained for all patients. Fourth, the attending
334	physicians and surgeons were not blinded to the MPI results, which might have affected the
335	clinical outcomes. Fifth, this study was performed in a tertiary hospital with high surgical
336	volumes, thus limiting its generalizability to lower-volume surgical centers.
337	In conclusion, among patients undergoing elective noncardiac surgery and referred for
338	preoperative MPI testing, an abnormal MPI study was associated with an increased risk of
339	30-day cardiac death or MI-a result that was independent of age, sex, and clinical risk
340	factors. However, the value of routine preoperative MPI testing appears to be limited given
341	its low positive predictive value and the fact that coronary angiography or revascularization
342	triggered by an abnormal MPI result was not associated with improved outcomes.
343	
344	Sources of Funding
345	This research was supported by a grant of the Korea Health Technology R&D Project through
346	the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health
347	& Welfare, Republic of Korea (grant number: HC19C0022).
348	
349	Role of the funding source
350	The funder of the study had no role in study design, data collection, data analysis, data

351 interpretation, or writing of the report.

353 Disclosures

354 The authors have no conflicts to declare.

355 References

356	1.	Weiser TG, Regenbogen SE, Thompson KD, Haynes AB, Lipsitz SR, Berry WR, Gawande AA.
357		An estimation of the global volume of surgery: a modelling strategy based on available
358		data. <i>Lancet</i> . 2008;372:139-144. doi: 10.1016/S0140-6736(08)60878-8
359	2.	Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, Fu R, Azad T, Chao
360		TE, Berry WR, et al. Estimate of the global volume of surgery in 2012: an assessment
361		supporting improved health outcomes. Lancet. 2015;385 Suppl 2:S11. doi: 10.1016/s0140-
362		6736(15)60806-6
363	3.	Spence J, LeManach Y, Chan MTV, Wang CY, Sigamani A, Xavier D, Pearse R, Alonso-Coello
364		P, Garutti I, Srinathan SK, et al. Association between complications and death within 30
365		days after noncardiac surgery. <i>Cmaj.</i> 2019;191:E830-e837. doi: 10.1503/cmaj.190221
366	4.	Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I,
367		Geisler T, Hinterbuchner L, et al. 2022 ESC Guidelines on cardiovascular assessment and
368		management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43:3826-3924.
369		doi: 10.1093/eurheartj/ehac270
370	5.	Etchells E, Meade M, Tomlinson G, Cook D. Semiquantitative dipyridamole myocardial
371		stress perfusion imaging for cardiac risk assessment before noncardiac vascular surgery: a
372		meta-analysis. <i>J Vasc Surg</i> . 2002;36:534-540. doi: 10.1067/mva.2002.126563
373	6.	Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, Ford I, Gonzalez-Juanatey
374		JR, Gorenek B, Heyndrickx GR, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery:
375		cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery:
376		cardiovascular assessment and management of the European Society of Cardiology (ESC)
377		and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383-2431. doi:
378		10.1093/eurheartj/ehu282
379	7.	Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-
380		Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, et al. 2014 ACC/AHA guideline on
381		perioperative cardiovascular evaluation and management of patients undergoing
382		noncardiac surgery: a report of the American College of Cardiology/American Heart
383		Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64:e77-137. doi:
384		10.1016/j.jacc.2014.07.944
385	8.	Devereaux PJ, Sessler DI. Cardiac Complications in Patients Undergoing Major Noncardiac
386		Surgery. N Engl J Med. 2015;373:2258-2269. doi: 10.1056/NEJMra1502824
387	9.	Smilowitz NR, Berger JS. Perioperative Cardiovascular Risk Assessment and Management
388		for Noncardiac Surgery: A Review. JAMA. 2020;324:279-290. doi: 10.1001/jama.2020.7840
389	10.	Wijeysundera DN, Beattie WS, Austin PC, Hux JE, Laupacis A. Non-invasive cardiac stress
390		testing before elective major non-cardiac surgery: population based cohort study. Bmj.

1.	Schulman-Marcus J, Feldman DN, Rao SV, Prasad A, McCoy L, Garratt K, Kim LK, Minutello
	RM, Wong SC, Vora AN, et al. Characteristics of Patients Undergoing Cardiac
	Catheterization Before Noncardiac Surgery: A Report From the National Cardiovascular
	Data Registry CathPCI Registry. JAMA Intern Med. 2016;176:611-618. doi:
	10.1001/jamainternmed.2016.0259
2.	Chan K, Abou-Zamzam AM, Woo K. Preoperative Cardiac Stress Testing in the Southern
	California Vascular Outcomes Improvement Collaborative. Ann Vasc Surg. 2018;49:234-240.
	doi: 10.1016/j.avsg.2017.11.028
3.	Shin SY, Lyu Y, Shin Y, Choi HJ, Park J, Kim WS, Lee JH. Lessons Learned from Development
	of De-identification System for Biomedical Research in a Korean Tertiary Hospital. Healthc
	Inform Res. 2013;19:102-109. doi: 10.4258/hir.2013.19.2.102
4.	Korean standard classification of diseases and causes of death (KCD-7).
	https://kssc.kostat.go.kr:8443/ksscNew_web/ekssc/main/main.do. Accessed 1 Apr 2016.
5.	Smilowitz NR, Gupta N, Ramakrishna H, Guo Y, Berger JS, Bangalore S. Perioperative Major
	Adverse Cardiovascular and Cerebrovascular Events Associated With Noncardiac Surgery.
	JAMA Cardiol. 2017;2:181-187. doi: 10.1001/jamacardio.2016.4792
6.	Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I,
	Geisler T, Hinterbuchner L, et al. 2022 ESC Guidelines on cardiovascular assessment and
	management of patients undergoing non-cardiac surgery: Developed by the task force for
	cardiovascular assessment and management of patients undergoing non-cardiac surgery
	of the European Society of Cardiology (ESC) Endorsed by the European Society of
	Anaesthesiology and Intensive Care (ESAIC). European Heart Journal. 2022;43:3826-3924.
	doi: 10.1093/eurheartj/ehac270
7.	Kim YH, Ahn JM, Park DW, Song HG, Lee JY, Kim WJ, Yun SC, Kang SJ, Lee SW, Lee CW, et
	al. Impact of ischemia-guided revascularization with myocardial perfusion imaging for
	patients with multivessel coronary disease. J Am Coll Cardiol. 2012;60:181-190. doi:
	10.1016/j.jacc.2012.02.061
8.	Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, Hayes SW,
	Cohen I, Germano G, Berman DS. Impact of ischaemia and scar on the therapeutic benefit
	derived from myocardial revascularization vs. medical therapy among patients undergoing
	stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32:1012-1024. doi:
	10.1093/eurheartj/ehq500
9.	Dorbala S, Ananthasubramaniam K, Armstrong IS, Chareonthaitawee P, DePuey EG, Einstein
	AJ, Gropler RJ, Holly TA, Mahmarian JJ, Park MA, et al. Single Photon Emission Computed
	Tomography (SPECT) Myocardial Perfusion Imaging Guidelines: Instrumentation,
	Acquisition, Processing, and Interpretation. J Nucl Cardiol. 2018;25:1784-1846. doi:
	7. 3. 9.

428 10.1007/s12350-018-1283-y

429 20. Son JS, Choi S, Kim K, Kim SM, Choi D, Lee G, Jeong SM, Park SY, Kim YY, Yun JM, et al. 430 Association of Blood Pressure Classification in Korean Young Adults According to the 2017 431 American College of Cardiology/American Heart Association Guidelines With Subsequent 432 Cardiovascular Disease Events. Jama. 2018;320:1783-1792. doi: 10.1001/jama.2018.16501 433 21. Ruetzler K, Smilowitz NR, Berger JS, Devereaux PJ, Maron BA, Newby LK, de Jesus Perez V, 434 Sessler DI, Wijeysundera DN. Diagnosis and Management of Patients With Myocardial 435 Injury After Noncardiac Surgery: A Scientific Statement From the American Heart 436 Association. Circulation. 2021;144:e287-e305. doi: 10.1161/CIR.000000000001024 437 22. Wijeysundera DN, Pearse RM, Shulman MA, Abbott TEF, Torres E, Ambosta A, Croal BL, 438 Granton JT, Thorpe KE, Grocott MPW, et al. Assessment of functional capacity before major 439 non-cardiac surgery: an international, prospective cohort study. The Lancet. 440 2018;391:2631-2640. doi: 10.1016/s0140-6736(18)31131-0 441 23. Dowsley TF, Sheth T, Chow BJW. Complementary pre-operative risk assessment using 442 coronary computed tomography angiography and nuclear myocardial perfusion imaging 443 in non-cardiac surgery: A VISION-CTA sub-study. J Nucl Cardiol. 2020;27:1331-1337. doi: 444 10.1007/s12350-019-01779-9 445 24. Hashimoto J, Nakahara T, Bai J, Kitamura N, Kasamatsu T, Kubo A. Preoperative risk 446 stratification with myocardial perfusion imaging in intermediate and low-risk non-cardiac 447 surgery. Circ J. 2007;71:1395-1400. doi: 10.1253/circj.71.1395 448 25. Metz LD, Beattie M, Hom R, Redberg RF, Grady D, Fleischmann KE. The prognostic value of 449 normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-450 analysis. J Am Coll Cardiol. 2007;49:227-237. doi: 10.1016/j.jacc.2006.08.048 451 26. Baron JF, Mundler O, Bertrand M, Vicaut E, Barré E, Godet G, Samama CM, Coriat P, Kieffer 452 E, Viars P. Dipyridamole-thallium scintigraphy and gated radionuclide angiography to 453 assess cardiac risk before abdominal aortic surgery. N Engl J Med. 1994;330:663-669. doi: 454 10.1056/nejm199403103301002 455 27. Shin S, Kwon TW, Cho YP, Lee JY, Park H, Han Y. Preoperative cardiac evaluation by 456 dipyridamole thallium-201 myocardial perfusion scan provides no benefit in patients with 457 abdominal aortic aneurysm. World J Surg. 2013;37:2965-2971. doi: 10.1007/s00268-013-458 2200-9 459 Yao Y, Quirk T, French M, Dharmalingam A, Collins N. Myocardial perfusion imaging failed 28. 460 to improve patient risk classification compared with the revised cardiac risk index for early 461 cardiac complications after major non-cardiac surgery. Intern Med J. 2022;52:1203-1214. 462 doi: 10.1111/imj.15662 463 29. Weinstein H, Steingart R. Myocardial perfusion imaging for preoperative risk stratification. 464 J Nucl Med. 2011;52:750-760. doi: 10.2967/jnumed.110.076158

465	30.	Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I,
466		Geisler T, Hinterbuchner L, et al. 2022 ESC Guidelines on cardiovascular assessment and
467		management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43:3826-3924.
468		doi: 10.1093/eurheartj/ehac270
469	31.	Gupta PK, Gupta H, Sundaram A, Kaushik M, Fang X, Miller WJ, Esterbrooks DJ, Hunter CB,
470		Pipinos, II, Johanning JM, et al. Development and validation of a risk calculator for
471		prediction of cardiac risk after surgery. Circulation. 2011;124:381-387. doi:
472		10.1161/circulationaha.110.015701
473	32.	Biccard B. Proposed research plan for the derivation of a new Cardiac Risk Index. Anesth
474		<i>Analg</i> . 2015;120:543-553. doi: 10.1213/ane.0000000000000598
475	33.	Biccard BM. The clinical utility of preoperative functional assessment. Lancet.
476		2018;391:2580-2581. doi: 10.1016/s0140-6736(18)31375-8
477	34.	McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S,
478		Rapp J, Hattler B, et al. Coronary-artery revascularization before elective major vascular
479		surgery. <i>N Engl J Med</i> . 2004;351:2795-2804. doi: 10.1056/NEJMoa041905
480	35.	Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. Risk of major
481		adverse cardiac events following noncardiac surgery in patients with coronary stents. Jama.
482		2013;310:1462-1472. doi: 10.1001/jama.2013.278787
483	36.	Poldermans D, Schouten O, Vidakovic R, Bax JJ, Thomson IR, Hoeks SE, Feringa HH,
484		Dunkelgrün M, de Jaegere P, Maat A, et al. A clinical randomized trial to evaluate the
485		safety of a noninvasive approach in high-risk patients undergoing major vascular surgery:
486		the DECREASE-V Pilot Study. J Am Coll Cardiol. 2007;49:1763-1769. doi:
487		10.1016/j.jacc.2006.11.052
488	37.	Muthappan P, Smith D, Aronow HD, Eagle K, Wohns D, Fox J, Share D, Gurm HS. The
489		epidemiology and outcomes of percutaneous coronary intervention before high-risk
490		noncardiac surgery in contemporary practice: insights from the Blue Cross Blue Shield of
491		Michigan Cardiovascular Consortium (BMC2) Registry. J Am Heart Assoc. 2014;3:e000388.
492		doi: 10.1161/jaha.113.000388
493	38.	Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR,
494		Senior R, López-Sendón J, Alexander KP, et al. Initial Invasive or Conservative Strategy for
495		Stable Coronary Disease. N Engl J Med. 2020;382:1395-1407. doi: 10.1056/NEJMoa1915922

497 Figure legends

- 498 Figure 1. Flow Diagram of Participants in the Study
- 499 MPI, myocardial perfusion imaging.
- 500 Figure 2. Frequency of Abnormal MPI According to the Revised Cardiac Risk Index
- 501 MPI, myocardial perfusion imaging.
- 502 Figure 3. Primary and Secondary Outcomes
- 503 The cumulative incidences of the primary outcome of the composite of cardiac death and
- 504 myocardial infarction (A) and the secondary outcomes of cardiac death (B), all-cause death
- 505 (C), and myocardial infarction (D) within 30 days of noncardiac surgery. The P value was
- 506 calculated by means of the log-rank test.

507 Figure 4. Primary and Secondary Outcomes According to Revised Cardiac Risk Index

- 508 Score
- 509 Subgroup analyses by revised cardiac risk index score for primary and secondary outcomes,
- classified into three groups (score of 0, 1, and ≥ 2). The crude incidence of the outcomes is
- 511 marked on the bars. P value for interaction is also shown.
- 512 Figure 5. Primary Outcome According to Preoperative Coronary Angiography and
- 513 Revascularization among Patients with Abnormal MPI Results
- 514 Cumulative incidences of the primary outcome of the composite of cardiac death and
- 515 myocardial infarction within 30 days after noncardiac surgery. CAG, coronary angiography;
- 516 MPI, myocardial perfusion imaging.

Table 1. Baseline Characteristics

	Myocardial perfusion imaging				
Characteristics	All patients	Abnormal	Normal	<i>P</i> value	
	(N = 82441)	(n = 5603)	(n = 76838)		
Age, mean (SD), years	65.7 (9.6)	67.5 (9.1)	65.5 (9.6)	<.001	
\geq 75 years	14581 (17.7)	1254 (22.4)	13327 (17.3)	<.001	
≥ 65 years	47926 (58.1)	3685 (65.8)	44241 (57.6)	<.001	
Sex (male)	47417 (57.5)	4500 (80.3)	42917 (55.9)	<.001	
BMI, mean (SD), kg/m^2	24.4 (3.4)	24.5 (3.4)	24.4 (3.5)	<.001	
Not available	2302 (2.8)	202 (3.6)	2100 (2.7)		
Hypertension	42570 (51.6)	3580 (63.9)	38990 (50.7)	<.001	
Diabetes	22295 (27.0)	2291 (40.9)	20004 (26.0)	<.001	
Insulin usage	3968 (4.8)	545 (9.7)	3423 (4.5)	<.001	
Hyperlipidemia	5407 (6.6)	670 (12.0)	4737 (6.2)	<.001	
Chronic kidney disease	4646 (5.6)	564 (10.1)	4082 (5.3)	<.001	
Creatinine $>2.0 \text{ mg/dL}$	3696 (4.5)	394 (7.0)	3302 (4.3)	<.001	
Chronic heart failure	1462 (1.8)	373 (6.7)	1089 (1.4)	<.001	
Cerebrovascular disease	3248 (3.9)	491 (8.8)	2757 (3.6)	<.001	
Ischemic heart disease	8218 (10.0)	3360 (60.0)	4858 (6.3)	<.001	
High-risk surgery	41396 (50.2)	2775 (49.5)	38621 (50.3)	.29	
Type of surgery				<.001	
General	33652 (40.8)	2380 (42.5)	31272 (40.7)		
Thoracic	5959 (7.2)	387 (6.9)	5572 (7.3)		
Transplant	5566 (6.8)	207 (3.7)	5359 (7.0)		
Vascular	2345 (2.8)	451 (8.0)	1894 (2.5)		
Urologic	7779 (9.4)	758 (13.5)	7021 (9.1)		
Breast and endocrine	947 (1.1)	67 (1.2)	880 (1.1)		
Neurosurgery	11106 (13.5)	427 (7.6)	10679 (13.9)		
Obstetrics and gynecology	2361 (2.9)	57 (1.0)	2304 (3.0)		
Orthopedic	10849 (13.2)	674 (12.0)	10175 (13.2)		
Otolaryngology	1492 (1.8)	136 (2.4)	1356 (1.8)		
Plastic	385 (0.5)	59 (1.1)	326 (0.4)		
Left ventricular ejection					
fraction					
$\leq 40\%$	712 (0.9)	349 (6.2)	363 (0.5)	<.001	
Not available	7342 (8.9)	218 (3.9)	7124 (9.3)		
Revised cardiac risk index				<.001	
0	32498 (39.4)	785 (14.0)	31713 (41.3)		
1	39837 (48.3)	2453 (43.8)	37384 (48.7)		
2	8445 (10.2)	1752 (31.3)	6693 (8.7)		
≥ 3	1661 (2.0)	613 (10.9)	1048 (1.4)		
Medication history*					
Beta blocker	16591 (20.1)	2862 (51.1)	13729 (17.9)	<.001	
Calcium channel blocker	38279 (46.4)	3693 (65.9)	34586 (45.0)	<.001	
ACEi or ARB	23904 (29.0)	2608 (46.5)	21296 (27.7)	<.001	

Statin	19981 (24.2)	3208 (57.3)	16773 (21.8)	<.001
Aspirin	9594 (11.6)	2684 (47.9)	6910 (9.0)	<.001
Clopidogrel	4896 (5.9)	1662 (29.7)	3234 (4.2)	<.001

518 Data are presented as no. (%) of individuals unless otherwise indicated.

519 *Medications at the time of admission for surgery.

520 Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor

521 blocker; SD, standard deviation.

	Myocardial perfusion imaging ^a		Unadjusted		Adjusted ^b	
	Abnormal	Normal	OR [95% CI]	<i>P</i> value	OR [95% CI]	P value
	n=5598	n=76790				
Primary outcome						
Cardiac death or MI	$69(1.2)^{a}$	115 (0.1)	8.32 [6.14-11.19]	<.001	4.64 [3.29-6.50]	<.001
Secondary outcomes						
Cardiac death	26 (0.5)	71 (0.1)	5.04 [3.16-7.80]	<.001	3.11 [1.86-5.07]	<.001
All-cause death	58 (1.0)	352 (0.5)	2.27 [1.70-2.98]	<.001	1.41 [1.03-1.89]	.026
MI	52 (0.9)	48 (0.1)	15.0 [10.11-22.26]	<.001	8.19 [5.21-12.87]	<.001
Patients undergoing troponin test ^c	n=3281	n=20638				
Cardiac death and MINS	548 (16.7)	2741 (13.3)	1.31 [1.18-1.45]	<.001	1.38 [1.24-1.53]	<.001
MINS	542 (16.5)	2729 (13.2)	1.30 [1.17-1.44]	<.001	1.37 [1.23-1.52]	<.001

522 Table 2. Thirty-day Outcomes, stratified by MPI Results

523 Abbreviations: CI, confidence interval; OR, odds ratio; MI, myocardial infarction; MINS, myocardial injury after noncardiac surgery.

^aCrude incidence within 30 days, no. of events (%).

^bAdjusted variables were age, sex, revised cardiac risk index, and myocardial perfusion imaging result.

⁵²⁶ ^cCardiac troponin test was conducted within 30 days after noncardiac surgery in 23934 patients, and 15 patients of them had missing data.

527 Table 3. Predictive Performance of Myocardial Perfusion Imaging before Noncardiac Surgery

		<i>P</i> value	Net reclassification improvement			
	AUC^{a}		Events	Non-events	Overall [95% CI]	<i>P</i> value
Cardiac death and MI						
Baseline model ^b	0.73					
Plus MPI result	0.77	<.001	-0.12	0.38	0.26 [0.11-0.40]	<.001
Cardiac death						
Baseline model ^b	0.70					
Plus MPI result	0.73	.048	-0.26	0.35	0.09 [-0.10-0.28]	.360
All cause death						
Baseline model ^b	0.65					
Plus MPI result	0.65	.110	-0.42	0.30	-0.12 [-0.21-0.03]	.007
Myocardial infarction						
Baseline model ^b	0.76					
Plus MPI result	0.83	<.001	0.10	0.49	0.59 [0.39-0.79]	<.001

528 Abbreviations: AUC, area under the receiver-operating-characteristic curve; CI, confidence interval; MPI, myocardial perfusion imaging.

⁵²⁹ ^aAUC for the relevant logistic regression model.

⁵³⁰ ^bCovariates in the baseline model were age, sex, and the revised cardiac risk index score.













B Cardiac death within 30 days after noncardiac surgery







